Acurx Pharmaceuticals, Inc. - 10-Q Filing
Acurx Pharmaceuticals filed its Q1 2025 10-Q report, disclosing financial and operational updates. The company reported a net loss of $0.05 per share for the three months ended March 31, 2025, with total liabilities increasing to reflect ongoing operations in drug development.
Tickers: $ACXP